Bayer files Eylea for DME approval in the EU
This article was originally published in Scrip
Bayer Healthcare has filed Eylea (aflibercept solution for injection (VEGF Trap-EYE)) for use in the additional indication of diabetic macular edema (DME) in the EU.
You may also be interested in...
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.